Breastfeeding may lower risk of ovarian cancer in women with BRCA mutations
https://www.facingourrisk.org/XRAY/breastfeeding-may-lower-ovarian-cancer-risk
Full article: https://linkinghub.elsevier.com/retrieve/pii/S0090-8258(20)33947-0
Data from a large-scale study suggests that breastfeeding may protect against ovarian cancer in women with inherited mutations in BRCA1 or BRCA2. (1/28/21)
Este artículo está disponible en español.
Questions To Ask Your Health Care Provider
- My family has a history of ovarian and breast cancers. Should I consider genetic testing for an inherited mutation?
- I have an inherited BRCA mutation. What are my options for managing my cancer risk?
- I have a BRCA mutation and I’m considering surgery. What is the best timing?
- I have a BRCA mutation and would like to have children. What issues should I consider in my family planning?
- I have a BRCA mutation and I am pregnant. How and when should I be screened for breast cancer?
- I have a BRCA mutation and I am nursing. How should I be screened for breast cancer?
- Should I consider oral contraceptives? If so, for how long?
Open Clinical Trials
The following are studies looking at ovarian cancer screening or prevention.
- NCT04251052: A Study to Compare Two Surgical Procedures in Women with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer (SOROCk). This study is looking at whether women with BRCA1 mutations who remove just the fallopian tubes can reduce the risk of ovarian cancer nearly as much as women who remove their ovaries and fallopian tubes.
- NCT05287451: Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention. This study will look at outcomes in women with BRCA1, BRCA2, BRIP1, RAD51C and RAD51D who remove their fallopian tubes, followed by removal of their ovaries compared to women who undergo standard-of-care removal of their ovaries and fallopian tubes at the same time.
- Validating a Blood Test for Early Ovarian Cancer Detection in High-risk Women and Families: MicroRNA Detection Study (MiDE). The goal of MiDe is to develop a test to detect early-onset ovarian cancer. Currently, no reliable screening or early detection tests are available. Participants can be expected to provide up to 4 tubes of blood every 6 months for up to 5 years. These samples can be collected by mobile phlebotomy all around the US.
Additional clinical trials for ovarian cancer screening and prevention may be found here.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.